Matinas BioPharma Holdings, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Schedule of Components of Accumulated Other Comprehensive (Loss)/Income (Details)

Schedule of Components of Accumulated Other Comprehensive (Loss)/Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Beginning Balance	$ (145)	$ 228
Accumulated Other Comprehensive (Loss)/Gain, Beginning Balance	(145)	228
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Net unrealized loss on securities available-for-sale	(679)	(373)
Accumulated Other Comprehensive (Loss)/Gain, Net unrealized loss on securities available-for-sale	(679)	(373)
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Ending Balance	(824)	(145)
Accumulated Other Comprehensive (Loss)/Gain, Ending Balance	$ (824)	$ (145)

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References + Details